LYRA
Lyra Therapeutics Inc (LYRA)
Healthcare • NASDAQ • $0.56-17.65%
- Symbol
- LYRA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.56
- Daily Change
- -17.65%
- Market Cap
- $1.21M
- Trailing P/E
- N/A
- Forward P/E
- -0.69
- 52W High
- $14.88
- 52W Low
- $0.31
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 0.69
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, S…
Company websiteResearch LYRA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.